PHASE 2

Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments for cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell-directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.

PHASE 3

We are building on a heritage of nearly a century in respiratory diseases, with treatments in asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis (IPF). Our R&D approach leverages our extensive expertise in respiratory medicine, inflammation and fibrosis to target a broad range of interstitial lung diseases such as IPF and systemic sclerosis-associated interstitial lung disease (SSc-ILD), as well as serious lung diseases with unmet patient needs, such as cystic fibrosis and severe asthma.

IMMUNOLOGY

Our R&D strategy is inspired by the courage of patients living with debilitating, life-limiting autoimmune conditions. We are taking bold steps to deliver scientific breakthroughs that target, repair and prevent these diseases. Specific areas of focus include inflammatory skin diseases and inflammatory bowel diseases such as Crohn’s Disease and Ulcerative Colitis.

CENTRAL NERVOUS SYSTEM DISEASES

Schizophrenia and treatment-resistant depression are key areas for R&D. Our approach focuses on understanding maladaptive brain circuitry to target the mechanisms directly responsible for major untreated symptom domains in neuropsychiatric diseases including cognitive impairment.

CARDIOMETABOLIC DISEASES

Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell-directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.

REPRODUCTIVE DISEASES

The ambition to prevent vision loss in people at risk, and preserve or restore vision in those with retinal diseases, is at the core of our R&D activities. Our extensive knowledge and insights from other therapeutic areas enable us to tackle the multifactorial pathophysiology of retinal diseases. Areas of focus include wet age-related macular degeneration, diabetic retinopathy and geographic atrophy.

ONCOLOGY

Cysteine protease inhibitor

Phosphodiesterase inhibitor

Appetite Modulator

Transient receptor potential channel inhibitor*

mRNA vaccine*

PD-1 antibody

VEGFR-2 antibody*

SMAC-mimetic

LRP 5/6 inhibitor*

SIRPα antagonist*

MEK Inhibitor*

Autotaxin inhibitor*

Cytokine receptor inhibitor

Receptor serine/threonine kinase inhibitor

TRP6 4/5 inhibitor*

Neuronal damage modulator

Atopic dermatitis

Crohn’s disease

Cystic fibrosis

Comprising heart failure

Cognitive impairment associated with schizophrenia

Chronic kidney disease

Potential new medicine approvals between 2019 and 2025

>60

New Molecular Entities anchor an innovation-led portfolio

>15

Clinical and pre-clinical pipeline projects

~100

Our Human Pharma Research and Development Pipeline

This represents a selection of assets in our research and development portfolio in June 2020.

>40

Pre-clinical development projects expected to deliver...

>15

New phase 1 starts in the next 12–18 months.

We are building on a heritage of nearly a century in respiratory diseases, with treatments in asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis (IPF). Our R&D approach leverages our extensive expertise in respiratory medicine, inflammation and fibrosis to target a broad range of interstitial lung diseases such as IPF and systemic sclerosis-associated interstitial lung disease (SSc-ILD), as well as serious lung diseases with unmet patient needs, such as cystic fibrosis and severe asthma.

In addition to building on our strengths in core therapeutic areas, we capture synergies by focusing research platforms on mechanisms such as immune modulation and fibrosis that contribute to multiple diseases. We focus expertise and resources to discover common pathophysiological mechanisms and accelerate the development of new medicines.

Our Research Beyond Borders function is exploring new frontiers in science and technology, both within and beyond our core therapeutic areas, to anticipate future developments of new medicines.

Our R&D strategy is inspired by the courage of patients living with debilitating, life-limiting autoimmune conditions. We are taking bold steps to deliver scientific breakthroughs that target, repair and prevent these diseases. Specific areas of focus include inflammatory skin diseases and inflammatory bowel diseases such as Crohn’s Disease and Ulcerative Colitis.

Our human Pharma pipeline projects expected to deliver...

>60

New molecular entities anchor an innovation-led portfolio.

>15

Potential new medicine approvals between 2019 and 2025.

50%

Of pipeline anchored to external collaborations.

Cardiometabolic Diseases

Oncology

Respiratory Diseases

ImmunoLOGY

Central Nervous System Diseases

Central Nervous System Diseases

Respiratory Diseases

Cardiometabolic Diseases

Pre-clinical development projects expected to deliver...

>40

New phase 1 starts in the next 12–18 months.

In addition to building on our strengths in core therapeutic areas, we capture synergies by focusing research platforms on mechanisms such as immune modulation and fibrosis that contribute to multiple diseases. We focus expertise and resources to discover common pathophysiological mechanisms and accelerate the development of new medicines.

Our Research Beyond Borders function is exploring new frontiers in science and technology, both within and beyond our core therapeutic areas, to anticipate future developments of new medicines.